NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT04553692 2025-03-28Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersIGM Biosciences, Inc.Phase 1 Terminated272 enrolled
NCT05087992 2025-02-19A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal CancersBoehringer IngelheimPhase 1 Completed13 enrolled 17 charts
NCT02726334 2019-01-16A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.Bionomics LimitedPhase 1 Terminated22 enrolled
NCT00813605 2016-10-27QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal CarcinomaNantCell, Inc.Phase 2 Completed155 enrolled
NCT00752570 2015-09-02A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaAmgenPhase 2 Completed144 enrolled
NCT00719199 2013-10-22Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal CancerEMD SeronoPhase 1 Terminated21 enrolled